CIK

GC Cell and BioCentriq® Execute Process Transfer Agreement in Anticipation of the U.S. entry of Immuncell-LC Inj.

Retrieved on: 
Monday, February 26, 2024
Transfer, Liver, Recurrence, Hepatocellular carcinoma, Risk, CDMO, CIK, Commercial, Odds, Cancer, Patient, Link, Brain, HCC, Mortality, Partnership, Pharmaceutical industry

(Link)

Key Points: 
  • (Link)
    Through this agreement with BioCentriq, GC Cell is accelerating the transfer of Immuncell-LC Inj.
  • YONGIN, South Korea and NEWARK, N.J., Feb. 26, 2024 /PRNewswire/ -- GC Cell , a fully integrated cell therapy pioneer has announced a strategic partnership with BioCentriq , a cell therapy contract development and manufacturing organization (CDMO) and US affiliate of GC Cell.
  • "The Process Transfer Agreement between GC Cell and BioCentriq initiates the groundwork for introducing Immuncell-LC to the U.S. market" said James Park, CEO of GC Cell.
  • "We are thrilled to partner with GC Cell to bring Immuncell-LC, a proven autologous cell therapy to the U.S. Market.

CIK Telecom Celebrates 20 Years of Excellence: A Strenuous Journey of Unfair Competition, Innovation, Customer Appreciation, and Community Impact

Retrieved on: 
Friday, September 15, 2023
Digital divide, Pressure, CIK, CIK Telecom, Telecommunications, Education, Internet service provider, Internet, IPTV, Mobile phone

This milestone marks two decades of delivering cutting-edge services, fostering customer relationships, and positively contributing to diverse communities across Canada.

Key Points: 
  • This milestone marks two decades of delivering cutting-edge services, fostering customer relationships, and positively contributing to diverse communities across Canada.
  • Founded in 2003, CIK Telecom embarked on a journey to transform the telecommunications landscape in Canada.
  • CIK Telecom's journey has been about more than just business growth, it has been about creating a positive impact.
  • In its 20th year and beyond, CIK Telecom remains committed to its core values of integrity, customer-centricity, and community engagement.

CoImmune Obtains License to Target DLL3 with IL-18 Armored CAR Technology

Retrieved on: 
Tuesday, June 27, 2023
SHIELD, Memorial Sloan Kettering Cancer Center, Roswell Park Comprehensive Cancer Center, Carcinoma, Interleukin, CIK, CD19, ALL, Acute lymphoblastic leukemia, Lymphoid leukemia, B cell, Armour, SCLC, CAR, Journal of Clinical Investigation, DLL3, Investigational New Drug, Chandos Chair of Medicine and Anatomy, MSK, PD-1, IND, Disease, Pharmaceutical industry, Vaccine

DURHAM, N.C., June 27, 2023 /PRNewswire/ -- CoImmune, Inc., a clinical stage immuno-oncology company working to redefine cancer treatment using best-in-class cellular immunotherapies, today announced it has exercised its option to obtain an exclusive license in the Delta-like Ligand 3 (DLL3)-targeted, allogeneic Chimeric Antigen Receptor-Cytokine Induced Killer (CAR-CIK) cell therapy field to interleukin-18 (IL-18) Armored CAR technology under a prior agreement with Memorial Sloan Kettering Cancer Center (MSK). The company is coupling the technology with allogeneic CIK cells and launched a development program focused on solid tumors with initial trials planned in small cell lung cancer (SCLC).

Key Points: 
  • CoImmune has the option to select up to three targets for IL-18 CAR products in the allogeneic cell therapy field under the agreement with MSK.
  • In March 2023, the company announced it had selected CD19 as the first target to support the clinical development of CMN-008 (Armored CAR-CIK cells) in B-cell malignancies.
  • The DLL3 target has been identified as a tumor-specific cell surface marker on neuroendocrine cancers including SCLC.
  • We saw strong synergy with PD1 checkpoint inhibition, suggesting a potential for curative responses at lower, subtherapeutic administrations of IL-18 armored anti-DLL3 CAR T cells.

TPA Project Finance Hopes to Empower Global Project Funding with Expedited Transactions

Retrieved on: 
Wednesday, June 14, 2023
CIK, TPA, Hope, Trust, Agility, Regulation, Cryptocurrency, Security (finance), Renewable energy

With a strong commitment to facilitating project funding across diverse industries, TPA Project Finance hopes to offer an efficient and expedited alternative to traditional banking institutions.

Key Points: 
  • With a strong commitment to facilitating project funding across diverse industries, TPA Project Finance hopes to offer an efficient and expedited alternative to traditional banking institutions.
  • "TPA Project Finance is new to the project funding landscape, and by offering a fully registered program, we really hope to make a splash," stated Clark Willis, the company's spokesperson.
  • TPA Project Finance's streamlined approach can enable clients to navigate the complexities of project funding with more ease.
  • To learn more about TPA Project Finance and project funding solutions, please visit their official website at www.tpaprojectfinance.com .

CoImmune Obtains License to IL-18 Armored CAR Technology

Retrieved on: 
Monday, March 20, 2023
Infection, Memorial Sloan Kettering Cancer Center, CIK, Roswell Park Comprehensive Cancer Center, CD19, Hospital, Lymphoid leukemia, Armour, CAR, Investigational New Drug, Chandos Chair of Medicine and Anatomy, MSK, FDA, IND, Vaccine, Pharmaceutical industry

The company plans to couple the technology with allogeneic Cytokine Induced Killer (CIK) cells to launch the clinical development of CMN-008 (Armored CAR-CIK cells) with CD19 as the initial target in B-cell malignancies.

Key Points: 
  • The company plans to couple the technology with allogeneic Cytokine Induced Killer (CIK) cells to launch the clinical development of CMN-008 (Armored CAR-CIK cells) with CD19 as the initial target in B-cell malignancies.
  • "We are pleased to obtain an exclusive license in the CD19-targeted, allogeneic cell therapy field to IL-18 Armored CAR technology developed by the renowned researchers at MSK that significantly strengthens our position as a leader in the field of immuno-oncology," said Charles Nicolette, Ph.D., Chief Executive Officer of CoImmune.
  • The CIK cells are genetically modified using a non-viral bicistronic vector encoding both CAR-CD19 and IL-18 that ensures all CAR+ cells are IL-18+.
  • "In animal models evaluating IL-18 Armored CAR technology, there was an increase in durability of responses and anti-tumor activity without requiring lymphodepletion, which could be a real game changer and warrants further evaluation."

Naturepedic Celebrates 20 Years Transforming People's Lives Through Safer and Healthier Sleep Options

Retrieved on: 
Monday, January 30, 2023
System, Good Housekeeping, OTA, Environment, Organic, NAPPA, HPD, Sleep, Real, Organic Trade Association, PETA, AECO, Architecture, JPMA, Lifestyle, Parent, Organization, Juvenile Products Manufacturers Association, Hearing, CIK, Nursing, Boilermaker, Toy, Engineering

CHAGRIN FALLS, Ohio, Jan. 30, 2023 /PRNewswire/ -- Naturepedic, makers of certified organic, non-toxic mattress and bedding products for babies, kids and adults, is thrilled to announce the celebration of its 20th anniversary year. Now, more than ever, this leader in organic sleep options is determined to continue its mission of providing trusted and healthier sleep alternatives in a sustainable and environmentally responsible way.

Key Points: 
  • Now, more than ever, this leader in organic sleep options is determined to continue its mission of providing trusted and healthier sleep alternatives in a sustainable and environmentally responsible way.
  • What started as the search for the perfect crib mattress became a lifelong commitment for the Cik family.
  • With the launch of the first non-toxic and certified organic mattress in 2003, Naturepedic was born.
  • To learn more about the Naturepedic's founder, click the following link to access the " 20 Questions with Naturepedic's Founder to Kickstart our 20th Year ."

U.S Dividend Reclassification Subscription 2023: Validate Your Primary Providers and Research Customer Enquiries - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 5, 2023
Professional Services, Finance, Trust, CFI, Research, NAICS, Security, NRA, SIC, Classification, Broker, Country, CIK, Database, Real estate investment trust, Security (finance), Ticker

The "U.S Dividend Reclassification" database has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "U.S Dividend Reclassification" database has been added to ResearchAndMarkets.com's offering.
  • The US Dividend Reclassification service can be utilized to create 1099s for your clients, as a secondary source to validate your primary provider, or as a tool for your client support group to research customer inquiries.
  • The files also contain the specific income classifications needed for accurate and timely income tax reporting for each dividend payable on the security.
  • North America - US Open-Ended Funds, Closed-End Funds, Exchange Traded Funds, and Real Estate Investment Trust.

CoImmune Announces Presentation of Results from Phase I/II Clinical Trial of CARCIK-CD19 in B-Cell Acute Lymphoblastic Leukemia at ASH Annual Meeting and Exposition

Retrieved on: 
Tuesday, December 13, 2022
Exposition, Phase, Hematology, Hematopoietic stem cell transplantation, American Society of Hematology, Pediatrics, B-ALL, Society, CIK, Patient, CR, HSCT, Monza, Acute lymphoblastic leukemia, Cell, Science, CAR, University, EFS, MRD, ASH, University of Milano-Bicocca, Risk, Pharmaceutical industry

DURHAM, N.C., Dec. 13, 2022 /PRNewswire/ -- CoImmune, Inc., a clinical stage immuno-oncology company working to redefine cancer treatment using best-in-class cellular immunotherapies, today announced the presentation of results from a Phase I/II clinical trial evaluating CARCIK-CD19, an investigational treatment based on the company's chimeric antigen receptor (CAR) modified cytokine induced killer (CIK) cell platform, in pediatric and adult patients with B-cell acute lymphoblastic leukemia (B-ALL) who had relapsed following hematopoietic stem cell transplantation (HSCT). The results are being presented at the American Society of Hematology's (ASH) 64th Annual Meeting and Exposition held December 10-13 in New Orleans.

Key Points: 
  • The results are being presented at the American Society of Hematology's (ASH) 64th Annual Meeting and Exposition held December 10-13 in New Orleans.
  • "In the Phase I/II dose-finding study, CARCIK-CD19 cells demonstrated an excellent safety profile with anti-leukemia activity in heavily pretreated patients with B-ALL relapsed after HSCT.
  • Importantly, the persistence of these cells was associated with a longer duration of response and reduced risk of leukemia relapse."
  • CoImmune is also announcing the presentation two additional preclinical studies at the ASH Annual Meeting that evaluated the CAR-CIK strategy in acute myeloid leukemia (AML).

CIK Telecom is proud to announce the launch of 10GB Fibre Internet to thousands of homes in Markham

Retrieved on: 
Monday, August 8, 2022
Aurora, Bell, City, CEO, GLOBE, Failure, Digital television, Internet service provider, FTTB, Communication, Rogers, FTTH, Home security, Lists of television programs, Lehigh Line Connection, CIK, DSL, Mobile, POI, UPS, Digital, CIK Telecom, Internet, Landline, Telecom, Mobile phone, Cable television, Online shopping

CIK Telecom offers both residential and business telecom services, including high-speed internet, home phone, digital TV, cell phone and home security services.

Key Points: 
  • CIK Telecom offers both residential and business telecom services, including high-speed internet, home phone, digital TV, cell phone and home security services.
  • SuperFibre Communication is responsible for developing, constructing and maintaining its own fibre internet networks for CIK Group, including FTTB (Fibre-To-The Building), FTTH (Fibre-to-the-House), and Air Fibre internet.
  • SuperFibre communications is building its own fibre network in Canada using fibre optic technology, the latest innovation in internet connectivity.
  • CIK Telecom offers both residential and business telecom services, including high-speed Cable and DSL internet, Fibre internet, Home Phone, Digital TV and Home Security services.

BioEclipse Therapeutics™ Awarded Almost $8 Million Grant by California Institute for Regenerative Medicine (CIRM) to Fund Ongoing Phase 1 CRX100 Cancer Immunotherapy Clinical Trial

Retrieved on: 
Tuesday, April 26, 2022
Moores Cancer Center, CIRM, Recurrence, Osteosarcoma, California Institute for Regenerative Medicine, Clinical trial, Stomach, Immunotherapy, Doctor of Philosophy, Stanford University, Patient, Goal, Hepatocellular carcinoma, Trial of the century, Technology, Triple-negative breast cancer, Principal, Method, Regenerative medicine, UC, Colorectal cancer, Safety, Disease, Ovarian cancer, Cancer, Therapy, CIK, Pharmaceutical industry, Vaccine

MOUNTAIN VIEW, Calif., April 26, 2022 /PRNewswire/ -- BioEclipse Therapeutics™ (BioEclipse), a privately held, clinical-stage biopharmaceutical company with a proprietary platform for developing next-generation cancer immunotherapies, announced today it has been awarded a $7,999,689.00 grant by the California Institute for Regenerative Medicine (CIRM) to support its ongoing clinical study: A Phase 1, open-label, dose-escalation study of CRX100 in patients with advanced solid tumors.

Key Points: 
  • BioEclipse is performing a Phase 1 clinical study evaluating the safety and tolerability of CRX100, a first-in-class immunotherapy that pairs the power of an oncolytic virus with the tumor-locating ability of cytokine-induced killer (CIK) cells.
  • Our technology harnesses two distinct methods of actionusing immune cells loaded with a cancer-killing virus that targets cancer tissue but spares healthy tissue.
  • The trial locations also include HonorHealth Research Institute in Scottsdale, Arizona, and UC San Diego Moores Cancer Center in La Jolla, California.
  • BioEclipse Therapeutics has started a Phase 1 clinical trial with CRX100, a patented, first-in-class, intravenously delivered, targeted immunotherapy against solid tumors.